Answers are grounded in this paper and cite their sources.
Growing evidence over recent years has established a bidirectional relationship between gut dysbiosis and mental health. This paper proposes that gut microbial imbalance and related functional disturbances may represent a plausible, testable biological modifier of psychotropic treatment response, contributing to apparent treatment resistance rather than only constituting a primary psychiatric cause. Stratifying patients by simple clinical and laboratory markers of dysbiosis could clarify heterogeneity in treatment outcomes. Psychotropic medications—although essential in treatment—may themselves induce or exacerbate dysbiosis, potentially contributing to indirect worsening of psychiatric symptoms in susceptible individuals. Conversely, alterations in the gut microbiome may influence the pharmacokinetics and pharmacodynamics of these agents, offering a plausible explanation for inter‑individual variability in response. Recognising dysbiosis as a clinically relevant factor may therefore refine our understanding of heterogeneous response profiles. Future directions should prioritise clinician education, patient awareness, and stratification of psychotropics by microbiome impact, advancing more personalised and biologically informed psychopharmacological care.
No takes yet. Share an insight, caveat, or question.
Mohammed Khaled Al Alaili (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: